Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on Oct 12, 2022 5:36am
303 Views
Post# 35018837

RE:RE:Just simmering

RE:RE:Just simmeringThanks for opening the door AZ. My investment in 37,717 shares of Promis at $7.13 cost basis is not a big fat ZERO. At yesterday's closing of $6.18, my investment is worth $230,000 and PMN's market cap was a paltry $45M. On September 27, 2022, Biogen with partner Eisai announced their phase 3 trial results of Lecanemab which modestly reduced the rate of decline in ALZ disease. This was the first positive results for an ALZ drug. This success is limited and there are side effects that will limit it as well. The drug is based on the amyloid beta theory, the same theory as PMN310. With this announcement, Biogen's stock increased from $198 per share to $268 per share or $70 per share on 146M shares or a market cap increase of $10 Billion dollars. Hmmm, WOW. 

PMN310 specifically and selectively targets toxic oligomers which makes it superior to Lecanemab. PMN310 has had total success in mice and non-human primates. It has had success with brain extracts with ALZ disease. PMN310 has a lower risk of ARIA, which is brain blood bleeding, than Lecanemab. PMN310 previously had slides that compared PMN310 to Lecanemab in a third party study. It looks like they are now just posting their current presentation. That study showed that PMN310 was substantially superior to Lecanemab and that the potential side effects were very substantially less. 

So, by next summer we should have a good idea about the success of PMN310. With that presumed success, lets add $5 billion to PMN's market cap of and you have a 100+ times increase in market cap and a 100+ times increase in the stock price or $600+ per share. It of course sounds crazy. So, I have invested in the positive science and results of PMN310 over the past five years. There is incedible potential upside. You don't often get a situation like this. I am very confident. I believe there will be several news off ramps in the first half of 2023 that will enable me to pull out my $269k investment and hold the balance of shares.
<< Previous
Bullboard Posts
Next >>